Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Evemie Schutyser"'
Supplementary Data I from Deletion of the COOH-Terminal Domain of CXC Chemokine Receptor 4 Leads to the Down-regulation of Cell-to-Cell Contact, Enhanced Motility and Proliferation in Breast Carcinoma Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d8fbc4860a2ca71a70fe168cfb6ea96
https://doi.org/10.1158/0008-5472.22365234
https://doi.org/10.1158/0008-5472.22365234
Supplementary Data II from Deletion of the COOH-Terminal Domain of CXC Chemokine Receptor 4 Leads to the Down-regulation of Cell-to-Cell Contact, Enhanced Motility and Proliferation in Breast Carcinoma Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29cec6c4df0806af493d35d19f32a109
https://doi.org/10.1158/0008-5472.22365231.v1
https://doi.org/10.1158/0008-5472.22365231.v1
The CXC chemokine receptor 4 (CXCR4) contributes to the metastasis of human breast cancer cells. The CXCR4 COOH-terminal domain (CTD) seems to play a major role in regulating receptor desensitization and down-regulation. We expressed either wild-type
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c4ba3660f14b421f5019c06f2925028
https://doi.org/10.1158/0008-5472.c.6494595.v1
https://doi.org/10.1158/0008-5472.c.6494595.v1
Autor:
Paul Proost, Willy Put, Sandra Nuyts, Jozef Van Damme, René Conings, Reinhilde Jacobs, Evemie Schutyser, Katleen Michiels, Sofie Struyf, Pierre Delaere, Jean-Pierre Lenaerts
Publikováno v:
European Journal of Oral Sciences. 117:362-368
Chemokines are important in inflammation and in carcinogenesis. We hypothesized that besides oro-laryngeal cancer, oral inflammatory states, such as periodontitis, may also influence the chemokine profile of oral fluid. The aim of this study was to c
Autor:
Hannelien Verbeke, Samuel Noppen, Paul Proost, Karel Geboes, Evemie Schutyser, Sofie Struyf, Mieke Gouwy, Ghislain Opdenakker, Raphael Sciot, Willy Put, Jo Vandercappellen, René Conings, Jozef Van Damme
Publikováno v:
Journal of Leukocyte Biology. 82:1519-1530
Chemokines affect inflammation and cancer through leukocyte attraction and angiogenesis. Here, we demonstrate that CXCL4L1/platelet factor-4 variant (PF-4var), a highly angiostatic chemokine, is poorly chemotactic for phagocytes and is inducible in m
Autor:
Evemie Schutyser, Paul Proost, Mieke Gouwy, Jozef Van Damme, Anneleen Mortier, Marc Parmentier, Tamara Loos, Jo Vandercappellen, Sofie Struyf, Isabelle Ronsse, Willy Put
Publikováno v:
Blood. 110:37-44
CXCR3 ligands were secreted by tissue fibroblasts and peripheral blood–derived mononuclear leukocytes in response to interferon-γ (IFN-γ) and Toll-like receptor (TLR) ligands. Subsequent purification and identification revealed the presence of tr
Publikováno v:
Cancer Research. 66:5665-5675
The CXC chemokine receptor 4 (CXCR4) contributes to the metastasis of human breast cancer cells. The CXCR4 COOH-terminal domain (CTD) seems to play a major role in regulating receptor desensitization and down-regulation. We expressed either wild-type
Publikováno v:
Cytokine & Growth Factor Reviews. 16:637-658
The internalization and intracellular trafficking of chemokine receptors have important implications for the cellular responses elicited by chemokine receptors. The major pathway by which chemokine receptors internalize is the clathrin-mediated pathw
Autor:
Jozef Van Damme, Genevieve Laureys, Yves Benoit, Sofie Struyf, Mieke Gouwy, Klara Gijsbers, Paul Proost, Ghislain Opdenakker, Evemie Schutyser
Publikováno v:
The American Journal of Pathology. 163:2065-2075
Chemokines play an important role in leukocyte mobilization, hematopoiesis, and angiogenesis. Tissue-specific expression of particular chemokines also influences tumor growth and metastasis. Here, the CC chemokine pulmonary and activation-regulated c
Autor:
Evemie Schutyser, Adelin Albert, Max Dratwa, Bart Maes, Frédéric Debelle, Gert Meeus, Raymond Vanholder, Michel Jadoul
Publikováno v:
Acta clinica Belgica. 68(4)
In Belgium, the calcimimetic cinacalcet is initially reimbursed foror = 4 months in dialysis patients with secondary hyperparathyroidism (SHPT) and intact parathyroid hormone (iPTH)or = 800 pg/mL, or iPTH 300-800 pg/ mL and Ca x P55 mg 2/dL2 despiteo